Open Access<p>The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile</p>
Author(s) -
Nicola Squillace,
Elena Ricci,
Barbara Menzaghi,
Giuseppe Vittorio De Socio,
Simone Passerini,
Canio Martinelli,
M. Mameli,
Paolo Maggi,
Katia Falasca,
Laura Cordier,
Benedetto Maurizio Celesia,
E Salomoni,
Antonio Di Biagio,
Giovanni Francesco Pellicanò,
Paolo Bonfanti
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
ISSN - 1177-8881
DOI - 10.2147/dddt.s274307
Subject(s) - tenofovir alafenamide , medicine , interquartile range , gastroenterology , viral load , endocrinology , pharmacology , human immunodeficiency virus (hiv) , antiretroviral therapy , immunology
We aimed to investigate the effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on the hepatic safety and metabolic profile.